{"id":6530,"date":"2021-11-15T18:44:20","date_gmt":"2021-11-15T10:44:20","guid":{"rendered":"https:\/\/www.excelsiormedical.com.tw\/?p=6530"},"modified":"2023-01-14T19:10:23","modified_gmt":"2023-01-14T11:10:23","slug":"announcement-according-to-the-article-25-1-3-and-25-1-4-of-regulations-governing-loaning-of-funds-and-making-of-endorsements-guarantees-by-public-companies","status":"publish","type":"post","link":"https:\/\/www.excelsiormedical.com.tw\/en\/investors\/announcement-according-to-the-article-25-1-3-and-25-1-4-of-regulations-governing-loaning-of-funds-and-making-of-endorsements-guarantees-by-public-companies\/","title":{"rendered":"Announcement according to the Article 25.1.3 and 25.1.4 of Regulations Governing Loaning of Funds and Making of Endorsements\/Guarantees by Public Companies."},"content":{"rendered":"

 <\/p>\n\n\n\n\n\n\n
SEQ_NO<\/td>\n\u00a02<\/td>\nDate of announcement<\/td>\n2021\/11\/15<\/td>\nTime of announcement<\/td>\n18:44:00<\/td>\n<\/tr>\n
Subject<\/td>\n\n
Announcement according to the Article 25.1.3 and\r\n25.1.4 of Regulations Governing Loaning of Funds and\r\nMaking of Endorsements\/Guarantees by Public Companies.<\/pre>\n<\/td>\n<\/tr>\n
Date of events<\/td>\n2021\/11\/15<\/td>\nTo which item it meets<\/td>\nparagraph 22<\/td>\n<\/tr>\n
Statement<\/td>\n\n
1.Date of occurrence of the event:2021\/11\/15\r\n2.For the company for whom the endorsements\/guarantees\r\n  were made, please specify name of endorsed\/guaranteed \r\n  company, its relationship with the Company providing\r\n  endorsements\/guarantees, the ceiling on the \r\n  endorsements \/guarantees (thousand NTD), the original\r\n  amount of endorsements\/guarantees (thousand NTD), the\r\n  amount of the current additional endorsements\/ \r\n  guarantees (thousand NTD),  the amount of endorsements\r\n  \/guarantees as of the date of occurrence (thousand NTD)\r\n  , the actual loaned amount of the company for whom \r\n  endorsements\/guarantees were made (thousand NTD), and \r\n  the reason for the current additional endorsements\/\r\n  guarantees:\r\n(1)Name of endorsed\/guaranteed company: \r\n   Excelsior Medical (HK) Co., Limited\r\n(2)Its relationship with the Company providing \r\n   endorsements\/guarantees: 100% wholly owned subsidiary\r\n(3)The ceiling on the endorsements\/guarantees (thousand\r\n   NTD): NT$ 1,505,488 thousands.\r\n(4)The original amount of endorsements\/guarantees \r\n   (thousand NTD):NT$ 0.\r\n(5)The amount of the current additional endorsements\/\r\n   guarantees(thousand NTD): NT$ 770,280 thousands.\r\n(6)The amount of endorsements\/guarantees as of the date\r\n   of occurrence (thousand NTD): NT$ 770,280 thousands.\r\n(7)The actual loaned amount of the company for whom \r\n   endorsements\/guarantees were made (thousand NTD):\r\n   NT$ 0.\r\n(8)The reason for the current additional endorsements\/\r\n   guarantees:\r\n   The company guarantee Excelsior Medical (HK) Co.,\r\n   Limited which acquires common shares of NephroCare \r\n   Limited and Cardinal Medical Services Ltd. in the \r\n   amount of NT$ 770,280 thousands for the execution \r\n   of contractual obligations and the payment of \r\n   transation prices.\r\n3.For collaterals provided by the company for whom \r\n  the endorsements\/ guarantees were made, the content\r\n  and the value (thousand NTD):  None.\r\n4.For the latest financial statements of the company \r\n  for whom the endorsements\/guarantees were made, the\r\n  Capital (thousand NTD) and Cumulative gains\/losses \r\n  (thousand NTD):\r\n  (1)Capital (thousand NTD): NT$ 2,451,275 thousands.\r\n  (2)Cumulative gains (thousand NTD): NT$ 130,655 \r\n     thousands.\r\n5.For termination of endorsement\/guarantee obligations,\r\n  the condition and the date:\r\n  (1)Condition: Excelsior Medical (HK) Co., Limited \r\n     completes the closing payment.\r\n  (2)Date: According to the Excelsior Medical (HK) Co.,\r\n     Limited 's closing payment schedule.\r\n6.The total amount of the ceiling on endorsements\/\r\n  guarantees (thousand NTD):NT$ 11,291,163 thousands.\r\n7.The total amount of endorsements\/guarantees as of \r\n  the date of occurrence (thousand NTD):NT$ 2,193,825\r\n  thousands.\r\n8.The amount of endorsements\/guarantees as a percentage\r\n  of the public company\u2019s net worth on the latest \r\n  financial report as of the date of occurrence:29.14%\r\n9.The aggregate amount of equity method investments,\r\n  endorsements\/guarantees, and monetary loans extended \r\n  to others as a percentage of the public company\u2019s net\r\n  worth on the latest financial statements:43.11%\r\n10.Any other matters that need to be specified:The \r\n   information is based on the balance of endorsement\/\r\n   guarantee in 2021.10.31.<\/pre>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n","protected":false},"excerpt":{"rendered":"
  SEQ_NO \u00a02 Date of announcement 2021\/11\/15 Time of announcement 18:44:00 Subject Announcement according to the Article 25.1.3 and 25.1.4 of Regulations Governing Loaning of Funds and Making of Endorsements\/Guarantees by Public Companies. Date of events 2021\/11\/15 To which item it meets paragraph 22 Statement 1.Date of occurrence of the event:2021\/11\/15 2.For the company for …<\/p>\n
  Announcement according to the Article 25.1.3 and 25.1.4 of Regulations Governing Loaning of Funds and Making of Endorsements\/Guarantees by Public Companies.<\/span> Read More »<\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","footnotes":"","_links_to":"","_links_to_target":""},"categories":[72,102],"tags":[],"class_list":["post-6530","post","type-post","status-publish","format-standard","hentry","category-investors","category-material-information"],"_links":{"self":[{"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/posts\/6530","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/comments?post=6530"}],"version-history":[{"count":10,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/posts\/6530\/revisions"}],"predecessor-version":[{"id":6958,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/posts\/6530\/revisions\/6958"}],"wp:attachment":[{"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/media?parent=6530"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/categories?post=6530"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/tags?post=6530"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}